Applied Therapeutics Inc (Applied Therapeutics) is a clinical-stage biopharmaceutical company that discovers and develops transformative drugs in areas of Galactosemia and Diabetic Cardiomyopathy (DbCM). The company product pipeline includes include AT-001 a novel aldose reductase inhibitor, AT-007 a SORD Deficiency, AT-001 a Diabetic Peripheral Neuropathy. Applied Therapeutics also develops preclinical pipeline product AT-003, an ARI designed for the treatment of diabetic retinopathy and AT-104 a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukaemia. It serves customers throughout the US. Applied Therapeutics is headquartered in New York, the US.
Applied Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
AT-001 - Diabetic complications, Diabetic Peripheral Neuropathy |
AT-007 - Rare Diseases |
XYZ |
XYZ |
XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Others | In January, the company submitted a new drug application for govorestat to the U.S. Food and Drug Administration. |
2023 | Contracts/Agreements | In January, the company announced a partnership with Advanz Pharma for commercialization of AT-007 (govorestat) in Europe. |
2022 | Others | In June, the company announced designation of AT-007 (gavorestat) as an orphan medicinal product by the European Medicines Agency (EMA) for treatment of Galactosemia (Galactosaemia). |
Competitor Comparison
Key Parameters | Applied Therapeutics Inc | Sage Therapeutics Inc | PhaseBio Pharmaceuticals Inc | BlueWillow Biologics Inc | Microbiotix Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | New York | Cambridge | Malvern | Ann Arbor | Worcester |
State/Province | New York | Massachusetts | Pennsylvania | Michigan | Massachusetts |
No. of Employees | 25 | 487 | 60 | - | - |
Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Shoshana Shendelman | Chairman; Chief Executive Officer; President | Executive Board | 2016 | 43 |
Riccardo Perfetti | Chief Medical Officer | Senior Management | 2018 | 62 |
Dale Hooks | Chief Commercial Officer | Senior Management | 2024 | - |
Les Funtleyder | Director | Non Executive Board | 2016 | 52 |
Teena Lerner | Director | Non Executive Board | 2017 | 64 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer